681247-11-0

Basic information

• Product Name: methyl 6-amino-3-bromo-2-hydroxybenzoate
• Synonyms: methyl 6-amino-3-bromo-2-hydroxybenzoate
• CAS NO: 681247-11-0
• Molecular Weight: 246.06
• Mol File: 681247-11-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 6-amino-3-bromo-2-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-amino-3-bromo-2-hydroxybenzoate(681247-11-0)
• EPA Substance Registry System: methyl 6-amino-3-bromo-2-hydroxybenzoate(681247-11-0)

Safety Data

• Hazardous Substances Data: 681247-11-0(Hazardous Substances Data)

Upstream product

• 681247-10-9 6-bromo-5-hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 
• 67765-42-8 5-methoxy-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 53600-33-2 6-methoxyanthranilic acid 
• 681247-09-6 6-bromo-5-methoxy-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 67-56-1 methanol 

Downstream Products

• 943138-76-9 C₁₅H₂₁BrN₂O₅ 
• 943138-78-1 C₁₄H₁₈BrNO₅ 
• 681247-12-1 methyl 6-amino-3-bromo-2-ethoxybenzoate 
• 681247-19-8 methyl 3-bromo-2-ethoxy-6-{[(4-fluorophenyl)sulfonyl]amino}benzoate 
• 681247-20-1 methyl 2-ethoxy-6-{[(4-fluorophenyl)sulfonyl]amino}-3-vinylbenzoate 
• 681247-21-2 methyl 2-ethoxy-3-ethyl-6-{[(4-fluorophenyl)sulfonyl]amino}benzoate 
• 943138-81-6 C₂₁H₂₄BrFN₂O₇S 
• 955937-54-9 C₂₃H₂₇FN₂O₇S 
• 955937-56-1 C₂₃H₂₉FN₂O₇S 
• 943138-86-1 C₂₂H₂₇FN₂O₇S 
• 943138-83-8 C₂₀H₂₁BrFNO₇S 
• 955937-58-3 C₂₂H₂₄FNO₇S 
• 955937-60-7 C₂₂H₂₆FNO₇S 
• 943138-88-3 C₂₁H₂₄FNO₇S 

Relevant articles and documents

Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids

A series of aryl sulfonamides of 5,6-disubstituted anthranilic acids were identified as potent inhibitors of methionine aminopeptidase-2 (MetAP2). Small alkyl groups and 3-furyl were tolerated at the 5-position of anthranilic acid, while -OCH3, CH3, and Cl were found optimal for the 6-position. Placement of 2-aminoethoxy group at the 6-position enabled interaction with the second Mn2+ but did not result in enhancement in potency. Introduction of a tertiary amino moiety at the ortho-position of the sulfonyl phenyl ring gave reduced protein binding and improved cellular activity, but led to lower oral bioavailability.

Sulfonamides having antiangiogenic and anticancer activity

Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.